Affitech is a privately held biotechnology company based in Oslo, Norway, that has developed a comprehensive package of innovative technologies for the generation and use of human antibodies. The most significant aspect of the Company’s proprietary technologies includes its dominant worldwide patent position on phagemid-display of antibodies.
Affitech was established in 1997 by a group of Norwegian and German Scientists. The Company’s mission is to become a leader in the discovery and development of proprietary antibody-based therapeutic products, addressing significant medical needs. In its pursuit of generating proprietary human antibodies for therapeutic and diagnostic use, the company has assembled an outstanding group of scientists with world-class experience. Affitech’s founder-team and Scientific Board comprises several pioneers and leading figures in the field of antibody engineering.